Elisabeth H Bel Selected Research

mepolizumab

3/2022	Development of methodology for assessing steroid-tapering in clinical trials for biologics in asthma.
1/2022	Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study).
1/2022	Health outcomes after stopping long-term mepolizumab in severe eosinophilic asthma: COMET.
1/2022	From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases.
6/2021	Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions.
1/2021	Long-Term Therapy Response to Anti-IL-5 Biologics in Severe Asthma-A Real-Life Evaluation.
1/2021	Clinical effects of mepolizumab in patients with severe eosinophilic asthma according to background therapy: A meta-analysis.
12/2020	Poor outcome of SARS-CoV-2 infection in patients with severe asthma on biologic therapy.
7/2020	Response to mepolizumab treatment is sustained across 4-weekly dosing periods.
1/2020	Usability of mepolizumab single-use prefilled syringe for patient self-administration.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Elisabeth H Bel Research Topics

Disease

67	Asthma (Bronchial Asthma) 11/2022 - 04/2002
11	Inflammation (Inflammations) 01/2022 - 04/2002
8	Eosinophilia 01/2019 - 04/2002
6	Chronic Obstructive Pulmonary Disease (COPD) 01/2022 - 12/2009
3	Airway Remodeling 01/2017 - 11/2007
2	Adrenal Insufficiency (Adrenal Gland Hypofunction) 01/2022 - 07/2019
2	Obesity 06/2021 - 11/2014
2	Obstructive Lung Diseases (Obstructive Lung Disease) 11/2019 - 02/2019
2	Allergic Rhinitis 01/2014 - 01/2013
1	Churg-Strauss Syndrome (Allergic Angiitis) 01/2022
1	Rhinosinusitis 01/2022
1	Hypereosinophilic Syndrome (Loeffler Endocarditis) 01/2022
1	Tachypnea 07/2021
1	Gastroesophageal Reflux (GERD) 06/2021
1	Diabetes Mellitus 06/2021
1	COVID-19 12/2020
1	Bronchial Spasm 11/2020
1	Pneumonia (Pneumonitis) 01/2019
1	Nasal Polyps (Nasal Polyp) 01/2018
1	Cough 11/2014
1	Pulmonary Embolism 09/2013
1	Respiratory Hypersensitivity 05/2013
1	Rhinitis 01/2013
1	Lung Abscess 11/2012
1	Takayasu Arteritis (Arteritis, Takayasu's) 11/2012
1	Long Term Adverse Effects 06/2011
1	Lung Diseases (Lung Disease) 10/2007
1	Respiratory Sounds (Crackle) 01/2004
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2004

Drug/Important Bio-Agent (IBA)

19	Adrenal Cortex Hormones (Corticosteroids)IBA 11/2022 - 09/2004
13	mepolizumabIBA 03/2022 - 09/2014
10	SteroidsIBA 03/2022 - 01/2004
10	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2007
8	Biological ProductsIBA 01/2022 - 11/2007
7	Nitric Oxide (Nitrogen Monoxide)FDA Link 11/2020 - 04/2002
6	Interleukin-5 (Interleukin 5)IBA 11/2022 - 08/2012
6	GlucocorticoidsIBA 07/2021 - 05/2013
5	benralizumabIBA 03/2022 - 07/2019
5	Prednisone (Sone)FDA LinkGeneric 01/2022 - 06/2011
4	dupilumabIBA 03/2022 - 12/2020
4	Bronchodilator Agents (Bronchodilators)IBA 06/2021 - 06/2011
4	Monoclonal AntibodiesIBA 11/2020 - 09/2014
4	Pharmaceutical PreparationsIBA 11/2019 - 04/2015
3	Interleukin-5 Receptors (Interleukin 5 Receptor)IBA 11/2022 - 01/2019
3	Prednisolone (Predate)FDA LinkGeneric 01/2022 - 05/2013
3	reslizumabIBA 01/2022 - 12/2020
3	Interleukin-13IBA 11/2020 - 01/2017
3	Immunoglobulin E (IgE)IBA 01/2019 - 01/2004
2	InterleukinsIBA 11/2022 - 01/2019
2	Proteins (Proteins, Gene)FDA Link 01/2022 - 12/2015
2	AllergensIBA 01/2021 - 12/2012
2	PeriostinIBA 01/2021 - 09/2013
2	CytokinesIBA 11/2020 - 01/2019
2	InterferonsIBA 01/2017 - 01/2014
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 11/2014 - 01/2004
1	Blood Proteins (Serum Proteins)IBA 01/2022
1	Hydrocortisone (Cortisol)FDA LinkGeneric 01/2022
1	Reducing AgentsIBA 01/2022
1	C-Reactive ProteinIBA 01/2022
1	Omalizumab (Xolair)FDA Link 12/2020
1	AlarminsIBA 11/2020
1	Interleukin-33IBA 11/2020
1	Thymic Stromal LymphopoietinIBA 11/2020
1	Interleukin-4 (Interleukin 4)IBA 11/2020
1	Plasminogen InactivatorsIBA 01/2016
1	Antifibrinolytic Agents (Antifibrinolytics)IBA 01/2016
1	Thrombin FDA Link 01/2016
1	Plasminogen Activator Inhibitor 1IBA 01/2016
1	fibrin fragment D (D-dimer)IBA 01/2016
1	antithrombin III-protease complexIBA 01/2016
1	Hemostatics (Antihemorrhagics)IBA 01/2016
1	Fibrinolysin FDA Link 01/2016
1	von Willebrand FactorIBA 01/2016
1	AnticoagulantsIBA 12/2015
1	drotrecogin alfa activated (Xigris)FDA Link 12/2015
1	Protein CIBA 12/2015
1	SmokeIBA 11/2014
1	4-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA 03/2014
1	Double-Stranded RNA (RNA, Double Stranded)IBA 01/2014
1	RNA (Ribonucleic Acid)IBA 09/2013
1	ORALIT (ORS)IBA 07/2013
1	SA 76IBA 07/2013
1	Methacholine Chloride (Methacholine)FDA Link 05/2013
1	Peptide Hydrolases (Proteases)FDA Link 01/2013
1	Immunoglobulins (Immunoglobulin)IBA 12/2012
1	tocilizumab (atlizumab)FDA Link 11/2012
1	Tiotropium Bromide (Spiriva)FDA Link 09/2012
1	ElastinIBA 06/2011
1	Volatile Organic CompoundsIBA 10/2007

Therapy/Procedure

15	Therapeutics 11/2022 - 11/2007
4	Biological Therapy 03/2022 - 11/2019
2	Bronchial Thermoplasty 01/2021 - 05/2006
2	Electronic Nose 12/2009 - 10/2007
1	Nebulizers and Vaporizers (Inhaler) 01/2022
1	Precision Medicine 10/2017